{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:15:22Z","timestamp":1792181722320,"version":"4.4.0"},"reference-count":263,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003339","name":"Consejo Superior de Investigaciones Cient\u00edficas","doi-asserted-by":"publisher","award":["202120E079"],"award-info":[{"award-number":["202120E079"]}],"id":[{"id":"10.13039\/501100003339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["AEI\/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["SEV-2013-0347"],"award-info":[{"award-number":["SEV-2013-0347"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["SEV-2017-0712"],"award-info":[{"award-number":["SEV-2017-0712"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022532","name":"Centro Nacional de Biotecnolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022532","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007258","name":"State University of New York","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007258","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023961","name":"Centro de Investigaci\u00f3n Biotecnol\u00f3gica en Red de Enfermedades Infecciosas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023961","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular Biology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jmb.2023.168173","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T11:33:22Z","timestamp":1686224002000},"page":"168173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases"],"prefix":"10.1016","volume":"435","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6276-7766","authenticated-orcid":false,"given":"Beatriz","family":"Perdiguero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8983-6784","authenticated-orcid":false,"given":"Patricia","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Marcos-Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Albericio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Astorgano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8308-7524","authenticated-orcid":false,"given":"Enrique","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6115-5610","authenticated-orcid":false,"given":"Laura","family":"Sin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Elena","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Garc\u00eda-Arriaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmb.2023.168173_b0005","series-title":"Encyclopedia of Virology","first-page":"322","article-title":"Poxviruses","author":"Smith","year":"2008"},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/v13010043","article-title":"There, and everywhere: the wide host range and geographic distribution of zoonotic orthopoxviruses","volume":"13","author":"Silva","year":"2020","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-065X.2010.00975.x","article-title":"Smallpox vaccines: targets of protective immunity","volume":"239","author":"Moss","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jmb.2023.168173_b0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.semcdb.2016.07.015","article-title":"Membrane fusion during poxvirus entry","volume":"60","author":"Moss","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.coviro.2011.11.007","article-title":"Poxvirus host cell entry","volume":"2","author":"Schmidt","year":"2012","journal-title":"Curr. Opin. Virol."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0030","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-virology-091919-104752","article-title":"The life cycle of the vaccinia virus genome","volume":"9","author":"Greseth","year":"2022","journal-title":"Ann. Rev. Virol."},{"issue":"10","key":"10.1016\/j.jmb.2023.168173_b0035","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.tim.2008.07.009","article-title":"Vaccinia virus morphogenesis and dissemination","volume":"16","author":"Roberts","year":"2008","journal-title":"Trends Microbiol."},{"issue":"7","key":"10.1016\/j.jmb.2023.168173_b0040","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3390\/biomedicines9070765","article-title":"Battle royale: innate recognition of poxviruses and viral immune evasion","volume":"9","author":"Yu","year":"2021","journal-title":"Biomedicines."},{"issue":"4","key":"10.1016\/j.jmb.2023.168173_b0045","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3390\/v7041726","article-title":"The evolution of poxvirus vaccines","volume":"7","author":"S\u00e1nchez-Sampedro","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.jmb.2023.168173_b0050","series-title":"Smallpox and its Eradication","author":"Fenner","year":"1988"},{"issue":"30","key":"10.1016\/j.jmb.2023.168173_b0055","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1016\/j.vaccine.2020.05.037","article-title":"Early smallpox vaccine manufacturing in the United States: Introduction of the \u201canimal vaccine\u201d in 1870, establishment of \u201cvaccine farms\u201d, and the beginnings of the vaccine industry","volume":"38","author":"Esparza","year":"2020","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.jmb.2023.168173_b0060","doi-asserted-by":"crossref","first-page":"e1007082","DOI":"10.1371\/journal.ppat.1007082","article-title":"Beyond the myths: Novel findings for old paradigms in the history of the smallpox vaccine","volume":"14","author":"Esparza","year":"2018","journal-title":"PLoS Pathog."},{"issue":"17\u201318","key":"10.1016\/j.jmb.2023.168173_b0065","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/j.vaccine.2005.01.012","article-title":"The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program","volume":"23","author":"Poland","year":"2005","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.jmb.2023.168173_b0070","doi-asserted-by":"crossref","first-page":"13049","DOI":"10.1128\/JVI.05779-11","article-title":"Genomic analysis of the vaccinia virus strain variants found in dryvax vaccine","volume":"85","author":"Qin","year":"2011","journal-title":"J. Virol."},{"issue":"49","key":"10.1016\/j.jmb.2023.168173_b0075","doi-asserted-by":"crossref","first-page":"8290","DOI":"10.1016\/j.vaccine.2007.09.050","article-title":"Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate","volume":"25","author":"Ferrier-Rembert","year":"2007","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.jmb.2023.168173_b0080","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1086\/432765","article-title":"Clinical responses to smallpox vaccine in vaccinia-naive and previously vaccinated populations: undiluted and diluted Lancy-Vaxina vaccine in a single-blind, randomized, prospective trial","volume":"192","author":"Kim","year":"2005","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.jmb.2023.168173_b0085","first-page":"251","article-title":"Smallpox vaccination: a review, part II. Adverse events. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of","volume":"37","author":"Fulginiti","year":"2003","journal-title":"America"},{"issue":"3","key":"10.1016\/j.jmb.2023.168173_b0090","first-page":"279","article-title":"Large-scale use of freeze-dried smallpox vaccine prepared in primary cultures of rabbit kidney cells","volume":"54","author":"Hekker","year":"1976","journal-title":"Bull. World Health Organ."},{"issue":"12","key":"10.1016\/j.jmb.2023.168173_b0095","doi-asserted-by":"crossref","first-page":"7845","DOI":"10.1128\/JVI.79.12.7845-7851.2005","article-title":"Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus","volume":"79","author":"Stittelaar","year":"2005","journal-title":"J. Virol."},{"issue":"9457","key":"10.1016\/j.jmb.2023.168173_b0100","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0140-6736(05)70234-8","article-title":"Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial","volume":"365","author":"Greenberg","year":"2005","journal-title":"Lancet (London, England)."},{"issue":"Suppl 2","key":"10.1016\/j.jmb.2023.168173_b0105","first-page":"S31","article-title":"ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)\u2013a second-generation smallpox vaccine for biological defense","volume":"8","author":"Monath","year":"2004","journal-title":"Int. J. Infect. Dis.: IJID: Off. Publ. Int. Soc. Infect. Dis."},{"issue":"36","key":"10.1016\/j.jmb.2023.168173_b0110","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1016\/j.vaccine.2010.06.063","article-title":"A randomized, double-blind, controlled clinical trial to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, in healthy volunteers","volume":"28","author":"Jang","year":"2010","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jmb.2023.168173_b0115","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/rmv.571","article-title":"New generation smallpox vaccines: a review of preclinical and clinical data","volume":"18","author":"Artenstein","year":"2008","journal-title":"Rev. Med. Virol."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2009.06.006","article-title":"Vaccinia virus vaccines: past, present and future","volume":"84","author":"Jacobs","year":"2009","journal-title":"Antiviral Res."},{"issue":"5","key":"10.1016\/j.jmb.2023.168173_b0125","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1348-0421.1985.tb00843.x","article-title":"Gene structures of low-neurovirulent vaccinia virus LC16m0, LC16m8, and their Lister original (LO) strains","volume":"29","author":"Sugimoto","year":"1985","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.jmb.2023.168173_b0130","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0264-410X(94)90215-1","article-title":"Characteristics of an attenuated vaccinia virus strain, LC16m0, and its recombinant virus vaccines","volume":"12","author":"Sugimoto","year":"1994","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.jmb.2023.168173_b0135","doi-asserted-by":"crossref","first-page":"11873","DOI":"10.1128\/JVI.79.18.11873-11891.2005","article-title":"An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection","volume":"79","author":"Morikawa","year":"2005","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0140","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/0042-6822(91)90480-Y","article-title":"Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteins","volume":"181","author":"Takahashi-Nishimaki","year":"1991","journal-title":"Virology"},{"issue":"Pt 12","key":"10.1016\/j.jmb.2023.168173_b0145","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1099\/0022-1317-83-12-2915","article-title":"The formation and function of extracellular enveloped vaccinia virus","volume":"83","author":"Smith","year":"2002","journal-title":"J. Gen. Virol."},{"issue":"8","key":"10.1016\/j.jmb.2023.168173_b0150","doi-asserted-by":"crossref","first-page":"4732","DOI":"10.1128\/jvi.67.8.4732-4741.1993","article-title":"Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination","volume":"67","author":"Wolffe","year":"1993","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0155","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/viro.1998.9516","article-title":"Neutralizing and protective antibodies directed against vaccinia virus envelope antigens","volume":"254","author":"Galmiche","year":"1999","journal-title":"Virology"},{"issue":"9","key":"10.1016\/j.jmb.2023.168173_b0160","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1128\/CVI.00199-14","article-title":"Safety of attenuated smallpox vaccine LC16m8 in immunodeficient mice","volume":"21","author":"Yokote","year":"2014","journal-title":"Clin. Vaccine Immunol."},{"issue":"45","key":"10.1016\/j.jmb.2023.168173_b0165","doi-asserted-by":"crossref","first-page":"6112","DOI":"10.1016\/j.vaccine.2015.07.076","article-title":"Vaccinia virus strain LC16m8 defective in the B5R gene keeps strong protection comparable to its parental strain Lister in immunodeficient mice","volume":"33","author":"Yokote","year":"2015","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jmb.2023.168173_b0170","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3390\/vaccines2040755","article-title":"Vaccinia virus LC16m8\u0394 as a vaccine vector for clinical applications","volume":"2","author":"Kidokoro","year":"2014","journal-title":"Vaccines (Basel)."},{"key":"10.1016\/j.jmb.2023.168173_b0175","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","article-title":"Modified vaccinia virus Ankara: history, value in basic research, and current perspectives for vaccine development","volume":"97","author":"Volz","year":"2017","journal-title":"Adv. Virus Res."},{"issue":"35","key":"10.1016\/j.jmb.2023.168173_b0180","first-page":"1149","article-title":"Intracutaneous smallpox vaccination with a weak pathogenic vaccinia virus (\u201cMVA virus\u201d)","volume":"113","author":"Stickl","year":"1971","journal-title":"Munch. Med. Wochenschr."},{"issue":"47","key":"10.1016\/j.jmb.2023.168173_b0185","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1055\/s-0028-1108143","article-title":"MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)","volume":"99","author":"Stickl","year":"1974","journal-title":"Dtsch. Med. Wochenschr."},{"issue":"8","key":"10.1016\/j.jmb.2023.168173_b0190","first-page":"253","article-title":"Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA","volume":"107","author":"Mahnel","year":"1994","journal-title":"Berl. Munch. Tierarztl. Wochenschr."},{"issue":"2","key":"10.1016\/j.jmb.2023.168173_b0195","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1006\/viro.1998.9123","article-title":"The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses","volume":"244","author":"Antoine","year":"1998","journal-title":"Virology"},{"issue":"Pt 5","key":"10.1016\/j.jmb.2023.168173_b0200","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1099\/0022-1317-72-5-1031","article-title":"Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence","volume":"72","author":"Meyer","year":"1991","journal-title":"J. Gen. Virol."},{"issue":"Pt 5","key":"10.1016\/j.jmb.2023.168173_b0205","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1099\/0022-1317-79-5-1159","article-title":"Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine","volume":"79","author":"Blanchard","year":"1998","journal-title":"J. Gen. Virol."},{"issue":"2","key":"10.1016\/j.jmb.2023.168173_b0210","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/viro.1998.9397","article-title":"Marker rescue of the host range restriction defects of modified vaccinia virus Ankara","volume":"251","author":"Wyatt","year":"1998","journal-title":"Virology"},{"issue":"22","key":"10.1016\/j.jmb.2023.168173_b0215","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.1073\/pnas.89.22.10847","article-title":"Nonreplicating vaccinia vector efficiently expresses recombinant genes","volume":"89","author":"Sutter","year":"1992","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2023.168173_b0220","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0042-6822(90)90294-2","article-title":"The complete DNA sequence of vaccinia virus","volume":"179","author":"Goebel","year":"1990","journal-title":"Virology"},{"issue":"51","key":"10.1016\/j.jmb.2023.168173_b0225","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.1016\/j.vaccine.2007.10.017","article-title":"Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge","volume":"25","author":"Frey","year":"2007","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.jmb.2023.168173_b0230","doi-asserted-by":"crossref","first-page":"e0157335","DOI":"10.1371\/journal.pone.0157335","article-title":"A Randomized, double-blind, placebo-controlled phase II Trial investigating the safety and immunogenicity of modified vaccinia Ankara smallpox vaccine (MVA-BN(R)) in 56\u201380-year-old subjects","volume":"11","author":"Greenberg","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jmb.2023.168173_b0235","doi-asserted-by":"crossref","first-page":"e0195897","DOI":"10.1371\/journal.pone.0195897","article-title":"Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial","volume":"13","author":"Overton","year":"2018","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jmb.2023.168173_b0240","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.vaccine.2006.10.047","article-title":"Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals","volume":"25","author":"Parrino","year":"2007","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.jmb.2023.168173_b0245","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1817307","article-title":"Phase 3 efficacy trial of modified vaccinia Ankara as a vaccine against smallpox","volume":"381","author":"Pittman","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jmb.2023.168173_b0250","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.vaccine.2009.11.030","article-title":"A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE","volume":"28","author":"von Krempelhuber","year":"2010","journal-title":"Vaccine"},{"issue":"6979","key":"10.1016\/j.jmb.2023.168173_b0255","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature02331","article-title":"Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox","volume":"428","author":"Earl","year":"2004","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0260","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/02648725.2018.1471643","article-title":"Vaccinia-based vaccines to biothreat and emerging viruses","volume":"34","author":"Nagata","year":"2018","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"10.1016\/j.jmb.2023.168173_b0265","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/192381a0","article-title":"A new mutant of dermovaccinia virus","volume":"192","author":"Tagaya","year":"1961","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jmb.2023.168173_b0270","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1006\/viro.2002.1622","article-title":"Structural analysis of vaccinia virus DIs strain: application as a new replication-deficient viral vector","volume":"302","author":"Ishii","year":"2002","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.jmb.2023.168173_b0275","doi-asserted-by":"crossref","first-page":"e1007710","DOI":"10.1371\/journal.ppat.1007710","article-title":"SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells","volume":"15","author":"Liu","year":"2019","journal-title":"PLoS Pathog."},{"issue":"7","key":"10.1016\/j.jmb.2023.168173_b0280","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1073\/pnas.1921098117","article-title":"Repair of a previously uncharacterized second host-range gene contributes to full replication of modified vaccinia virus Ankara (MVA) in human cells","volume":"117","author":"Peng","year":"2020","journal-title":"PNAS"},{"issue":"5","key":"10.1016\/j.jmb.2023.168173_b0285","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-3083.2008.02168.x","article-title":"Mucosal administration of completely non-replicative vaccinia virus recombinant Dairen I strain elicits effective mucosal and systemic immunity","volume":"68","author":"Yoshino","year":"2008","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.jmb.2023.168173_b0290","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/978-0-387-33012-9_107","article-title":"Highly attenuated vaccinia virus DIs as a potential SARS vaccine","volume":"581","author":"Ishii","year":"2006","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.jmb.2023.168173_b0295","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.967019","volume":"13","author":"Ishigaki","year":"2022","journal-title":"Front. Microbiol."},{"issue":"36","key":"10.1016\/j.jmb.2023.168173_b0300","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1016\/j.vaccine.2021.06.060","article-title":"Development of an attenuated smallpox vaccine candidate: The KVAC103 strain","volume":"39","author":"Lim","year":"2021","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0305","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12866-021-02121-5","article-title":"Construction of a bivalent vaccine against anthrax and smallpox using the attenuated vaccinia virus KVAC103","volume":"21","author":"Park","year":"2021","journal-title":"BMC Microbiol."},{"issue":"8","key":"10.1016\/j.jmb.2023.168173_b0310","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1089\/aid.1992.8.1445","article-title":"Highly attenuated poxvirus vectors","volume":"8","author":"Tartaglia","year":"1992","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0315","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0042-6822(92)90752-B","article-title":"NYVAC: a highly attenuated strain of vaccinia virus","volume":"188","author":"Tartaglia","year":"1992","journal-title":"Virology"},{"issue":"12","key":"10.1016\/j.jmb.2023.168173_b0320","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1128\/JVI.02108-05","article-title":"Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene","volume":"80","author":"Najera","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2023.168173_b0325","first-page":"125","article-title":"Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strain","volume":"82","author":"Tartaglia","year":"1994","journal-title":"NYVAC. Dev Biol Stand."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0330","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.20071331","article-title":"An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses","volume":"205","author":"Harari","year":"2008","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.jmb.2023.168173_b0335","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1016\/S2352-3018(19)30262-0","article-title":"Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial","volume":"6","author":"Pantaleo","year":"2019","journal-title":"Lancet HIV."},{"key":"10.1016\/j.jmb.2023.168173_b0340","unstructured":"Ruan, L., Zhu, J., Lou, T., Lu, R., (2006). Non-Replicating Vaccinia Virus Tian Tian. Patent 2006."},{"key":"10.1016\/j.jmb.2023.168173_b0345","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3389\/fcimb.2020.00116","article-title":"Non-replicating Vaccinia Virus TianTan Strain (NTV) Translation Arrest of Viral Late Protein Synthesis Associated With Anti-viral Host Factor SAMD9","volume":"10","author":"Zhao","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"5","key":"10.1016\/j.jmb.2023.168173_b0350","first-page":"358","article-title":"Construction of non\u2013replicating recombinant vaccinia virus expressing human papillomavirus 16E6\/E7 fusion protein and study of its immunogenicity and antitumor response. Bing du xue bao = Chinese","volume":"22","author":"Houwen","year":"2006","journal-title":"J. Virol."},{"issue":"15","key":"10.1016\/j.jmb.2023.168173_b0355","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.vaccine.2019.02.063","article-title":"Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates","volume":"37","author":"Zhan","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0360","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/s41467-018-03662-6","article-title":"A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses","volume":"9","author":"Prow","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0365","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41541-020-0191-8","article-title":"The vaccinia virus based Sementis Copenhagen Vector vaccine against Zika and chikungunya is immunogenic in non-human primates","volume":"5","author":"Prow","year":"2020","journal-title":"npj Vaccines"},{"issue":"4","key":"10.1016\/j.jmb.2023.168173_b0370","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/imcb.12539","article-title":"The vaccinia-based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses","volume":"100","author":"Eldi","year":"2022","journal-title":"Immunol. Cell Biol."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/br.37.1.1-18.1973","article-title":"Monkeypox virus","volume":"37","author":"Cho","year":"1973","journal-title":"Bacteriol. Rev."},{"issue":"5","key":"10.1016\/j.jmb.2023.168173_b0380","first-page":"593","article-title":"A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo","volume":"46","author":"Ladnyj","year":"1972","journal-title":"Bull. World Health Organ."},{"issue":"9","key":"10.1016\/j.jmb.2023.168173_b0385","doi-asserted-by":"crossref","first-page":"638","DOI":"10.2471\/BLT.19.242347","article-title":"Modelling human-to-human transmission of monkeypox","volume":"98","author":"Grant","year":"2020","journal-title":"Bull. World Health Organ."},{"issue":"2","key":"10.1016\/j.jmb.2023.168173_b0390","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1006\/viro.2002.1446","article-title":"Analysis of the monkeypox virus genome","volume":"297","author":"Shchelkunov","year":"2002","journal-title":"Virology"},{"issue":"37","key":"10.1016\/j.jmb.2023.168173_b0395","doi-asserted-by":"crossref","first-page":"16262","DOI":"10.1073\/pnas.1005769107","article-title":"Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo","volume":"107","author":"Rimoin","year":"2010","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0400","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41392-022-01181-x","article-title":"The monkeypox outbreak in 2022: adaptive evolution associated with APOBEC3 may account for","volume":"7","author":"Chen","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"11","key":"10.1016\/j.jmb.2023.168173_b0405","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.3390\/microorganisms10112192","article-title":"Animal models used in monkeypox research","volume":"10","author":"Doman","year":"2022","journal-title":"Microorganisms."},{"issue":"4","key":"10.1016\/j.jmb.2023.168173_b0410","first-page":"465","article-title":"Human monkeypox: secondary attack rates","volume":"66","author":"Jezek","year":"1988","journal-title":"Bull. World Health Organ."},{"issue":"3","key":"10.1016\/j.jmb.2023.168173_b0415","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.cell.2016.09.049","article-title":"Cross-neutralizing and protective human antibody specificities to poxvirus infections","volume":"167","author":"Gilchuk","year":"2016","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.jmb.2023.168173_b0420","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3390\/v14091960","article-title":"Vaccinia-virus-based vaccines are expected to elicit highly cross-reactive immunity to the 2022 monkeypox virus","volume":"14","author":"Ahmed","year":"2022","journal-title":"Viruses"},{"issue":"8","key":"10.1016\/j.jmb.2023.168173_b0425","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1128\/JVI.02012-09","article-title":"A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus","volume":"84","author":"Stabenow","year":"2010","journal-title":"J. Virol."},{"issue":"31","key":"10.1016\/j.jmb.2023.168173_b0430","doi-asserted-by":"crossref","first-page":"10889","DOI":"10.1073\/pnas.0804985105","article-title":"Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus","volume":"105","author":"Earl","year":"2008","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0435","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.virol.2007.04.010","article-title":"DNA\/MVA HIV-1\/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge","volume":"366","author":"Nigam","year":"2007","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.jmb.2023.168173_b0440","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/infdis\/jis753","article-title":"Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects","volume":"207","author":"Greenberg","year":"2013","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.jmb.2023.168173_b0445","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.vaccine.2005.11.022","article-title":"Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine","volume":"24","author":"Vollmar","year":"2006","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.jmb.2023.168173_b0450","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1093\/infdis\/jit105","article-title":"Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial","volume":"207","author":"Walsh","year":"2013","journal-title":"J Infect Dis"},{"issue":"RR-02","key":"10.1016\/j.jmb.2023.168173_b0455","first-page":"1","article-title":"Clinical guidance for smallpox vaccine use in a postevent vaccination program","volume":"64","author":"Petersen","year":"2015","journal-title":"MMWR Recomm. Rep."},{"key":"10.1016\/j.jmb.2023.168173_b0460","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.antiviral.2018.11.004","article-title":"Vaccinating against monkeypox in the Democratic Republic of the Congo","volume":"162","author":"Petersen","year":"2019","journal-title":"Antiviral Res."},{"issue":"50","key":"10.1016\/j.jmb.2023.168173_b0465","doi-asserted-by":"crossref","first-page":"7321","DOI":"10.1016\/j.vaccine.2022.10.078","article-title":"Serological responses to the MVA-based JYNNEOS monkeypox vaccine in a cohort of participants from the Democratic Republic of Congo","volume":"40","author":"Priyamvada","year":"2022","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.jmb.2023.168173_b0470","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/infdis\/jiac455","article-title":"One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines","volume":"227","author":"Ilchmann","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmb.2023.168173_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(23)00057-9","article-title":"Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study","author":"Bertran","year":"2023","journal-title":"Lancet Infect. Dis."},{"issue":"3","key":"10.1016\/j.jmb.2023.168173_b0480","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41591-023-02229-3","article-title":"Real-world effectiveness of a single dose of mpox vaccine in males","volume":"29","author":"Wolff Sagy","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.jmb.2023.168173_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102855","article-title":"The 2022 outbreak and the pathobiology of the monkeypox virus","volume":"131","author":"Kumar","year":"2022","journal-title":"J. Autoimmun."},{"issue":"22","key":"10.1016\/j.jmb.2023.168173_b0490","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm7122e1","article-title":"Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022","volume":"71","author":"Rao","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0495","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-022-02090-w","article-title":"Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals","volume":"29","author":"Zaeck","year":"2023","journal-title":"Nat. Med."},{"issue":"7798","key":"10.1016\/j.jmb.2023.168173_b0500","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"issue":"6965","key":"10.1016\/j.jmb.2023.168173_b0505","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2023.168173_b0510","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.748103","article-title":"The bacterial mucosal immunotherapy MV130 protects against SARS-CoV-2 infection and improves COVID-19 Vaccines Immunogenicity","volume":"12","author":"Del Fresno","year":"2021","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.jmb.2023.168173_b0515","doi-asserted-by":"crossref","first-page":"e02260","DOI":"10.1128\/JVI.02260-20","article-title":"COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice","volume":"95","author":"Garcia-Arriaza","year":"2021","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0520","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41541-022-00440-w","article-title":"Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice","volume":"7","author":"Lazaro-Frias","year":"2022","journal-title":"npj Vaccines"},{"key":"10.1016\/j.jmb.2023.168173_b0525","doi-asserted-by":"crossref","first-page":"1001951","DOI":"10.3389\/fimmu.2022.1001951","article-title":"Serum angiotensin-converting enzyme 2 as a potential biomarker for SARS-CoV-2 infection and vaccine efficacy","volume":"13","author":"Lennol","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jmb.2023.168173_b0530","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.995235","article-title":"Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection","volume":"13","author":"Perez","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jmb.2023.168173_b0535","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.824728","article-title":"A single dose of an MVA vaccine expressing a prefusion-stabilized SARS-CoV-2 spike protein neutralizes variants of concern and protects mice from a lethal SARS-CoV-2 infection","volume":"12","author":"Perez","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.jmb.2023.168173_b0540","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41593-022-01242-y","article-title":"Full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice conferred by MVA-CoV2-S vaccine candidate","volume":"26","author":"Villadiego","year":"2023","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jmb.2023.168173_b0545","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.845969","article-title":"MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters","volume":"13","author":"Boudewijns","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jmb.2023.168173_b0550","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.845887","article-title":"Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2","volume":"13","author":"Mooij","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0555","doi-asserted-by":"crossref","first-page":"6121","DOI":"10.1038\/s41467-020-19819-1","article-title":"Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform","volume":"11","author":"Chiuppesi","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0560","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-022-00436-6","article-title":"Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates","volume":"7","author":"Chiuppesi","year":"2022","journal-title":"npj Vaccines"},{"issue":"6","key":"10.1016\/j.jmb.2023.168173_b0565","first-page":"104457","volume":"25","author":"Wussow","year":"2022","journal-title":"COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants, iScience"},{"issue":"28","key":"10.1016\/j.jmb.2023.168173_b0570","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2026207118","article-title":"Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination","volume":"118","author":"Tscherne","year":"2021","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2023.168173_b0575","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.772240","article-title":"Intranasal Delivery of MVA vector vaccine induces effective pulmonary immunity against SARS-CoV-2 in rodents","volume":"12","author":"Bosnjak","year":"2021","journal-title":"Front. Immunol."},{"issue":"24","key":"10.1016\/j.jmb.2023.168173_b0580","doi-asserted-by":"crossref","first-page":"e159895","DOI":"10.1172\/JCI159895","article-title":"Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity","volume":"132","author":"Meyer Zu Natrup","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.jmb.2023.168173_b0585","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2026785118","article-title":"One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection","volume":"118","author":"Liu","year":"2021","journal-title":"PNAS"},{"issue":"24","key":"10.1016\/j.jmb.2023.168173_b0590","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2202069119","article-title":"Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection","volume":"119","author":"Americo","year":"2022","journal-title":"PNAS"},{"issue":"3","key":"10.1016\/j.jmb.2023.168173_b0595","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2021.02.001","article-title":"A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs","volume":"54","author":"Routhu","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.jmb.2023.168173_b0600","doi-asserted-by":"crossref","first-page":"eabo0226","DOI":"10.1126\/sciimmunol.abo0226","article-title":"A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection","volume":"772","author":"Routhu","year":"2022","journal-title":"Sci. Immunol."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0605","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41541-021-00410-8","article-title":"MVA vector expression of SARS-CoV-2 spike protein and protection of adult Syrian hamsters against SARS-CoV-2 challenge","volume":"6","author":"Meseda","year":"2021","journal-title":"npj Vaccines"},{"issue":"9","key":"10.1016\/j.jmb.2023.168173_b0610","doi-asserted-by":"crossref","first-page":"e0257191","DOI":"10.1371\/journal.pone.0257191","article-title":"Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters","volume":"16","author":"Kulkarni","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0615","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41541-021-00405-5","article-title":"Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies","volume":"6","author":"Zhong","year":"2021","journal-title":"npj Vaccines"},{"issue":"2","key":"10.1016\/j.jmb.2023.168173_b0620","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3390\/vaccines9020132","article-title":"Localized and systemic immune responses against SARS-CoV-2 following mucosal immunization","volume":"9","author":"Chandrasekar","year":"2021","journal-title":"Vaccines (Basel)."},{"issue":"11","key":"10.1016\/j.jmb.2023.168173_b0625","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41590-020-0778-2","article-title":"SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function","volume":"21","author":"Winkler","year":"2020","journal-title":"Nat. Immunol."},{"issue":"7843","key":"10.1016\/j.jmb.2023.168173_b0630","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41586-020-2943-z","article-title":"COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice","volume":"589","author":"Zheng","year":"2021","journal-title":"Nature"},{"issue":"7845","key":"10.1016\/j.jmb.2023.168173_b0635","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41586-020-3035-9","article-title":"A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate","volume":"590","author":"Sanchez-Felipe","year":"2021","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jmb.2023.168173_b0640","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/S2666-5247(22)00027-1","article-title":"Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial","volume":"3","author":"Chiuppesi","year":"2022","journal-title":"Lancet Microbe."},{"issue":"8","key":"10.1016\/j.jmb.2023.168173_b0645","doi-asserted-by":"crossref","first-page":"104745","DOI":"10.1016\/j.isci.2022.104745","article-title":"Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants","volume":"25","author":"Chiuppesi","year":"2022","journal-title":"iScience"},{"issue":"3","key":"10.1016\/j.jmb.2023.168173_b0650","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.cll.2004.05.008","article-title":"Major factors affecting the emergence and re-emergence of infectious diseases","volume":"24","author":"Church","year":"2004","journal-title":"Clin. Lab. Med."},{"key":"10.1016\/j.jmb.2023.168173_b0655","unstructured":"WHO. Prioritizing diseases for research and development in emergency contexts 2023 Available from: https:\/\/www.who.int\/activities\/prioritizing-diseases-for-research-and-development-in-emergency-contexts."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0660","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.antiviral.2013.07.006","article-title":"Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity","volume":"100","author":"Bente","year":"2013","journal-title":"Antiviral Res."},{"issue":"6","key":"10.1016\/j.jmb.2023.168173_b0665","doi-asserted-by":"crossref","first-page":"e0156637","DOI":"10.1371\/journal.pone.0156637","article-title":"Protective effects of a Modified Vaccinia Ankara-based vaccine candidate against Crimean-Congo Haemorrhagic Fever virus require both cellular and humoral responses","volume":"11","author":"Dowall","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jmb.2023.168173_b0670","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/769121","article-title":"Ebola virus disease 2013\u20132014 outbreak in west Africa: an analysis of the epidemic spread and response","volume":"2015","author":"Cenciarelli","year":"2015","journal-title":"Int. J. Microbiol."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0675","doi-asserted-by":"crossref","first-page":"12459","DOI":"10.1038\/s41598-018-31003-6","article-title":"DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune responses that can be further improved by a recombinant MVA boost","volume":"8","author":"Ohlund","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jmb.2023.168173_b0680","doi-asserted-by":"crossref","first-page":"e00343","DOI":"10.1128\/JVI.00343-17","article-title":"Recombinant modified vaccinia virus Ankara generating ebola virus-like particles","volume":"91","author":"Schweneker","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2023.168173_b0685","doi-asserted-by":"crossref","first-page":"e00363","DOI":"10.1128\/JVI.00363-18","article-title":"Distinct immunogenicity and efficacy of poxvirus-based vaccine candidates against ebola virus expressing GP and VP40 proteins","volume":"92","author":"L\u00e1zaro-Fr\u00edas","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2023.168173_b0690","unstructured":"WHO. Ebola virus disease 2023 Available from: https:\/\/www.who.int\/health-topics\/ebola#tab=tab_1."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0695","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0700","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/infdis\/jiz070","article-title":"Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a Phase 1 randomized clinical trial in Uganda and Tanzania","volume":"220","author":"Anywaine","year":"2019","journal-title":"J. Infect. Dis."},{"issue":"15","key":"10.1016\/j.jmb.2023.168173_b0705","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-Vectored Ebola vaccines: a randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"J. Am. Med. Assoc."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0710","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/infdis\/jiz071","article-title":"Safety and Immunogenicity of a 2-Dose heterologous vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Nairobi, Kenya","volume":"220","author":"Mutua","year":"2019","journal-title":"J. Infect. Dis."},{"issue":"10","key":"10.1016\/j.jmb.2023.168173_b0715","doi-asserted-by":"crossref","first-page":"e1003813","DOI":"10.1371\/journal.pmed.1003813","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa","volume":"18","author":"Barry","year":"2021","journal-title":"PLoS Med."},{"issue":"10","key":"10.1016\/j.jmb.2023.168173_b0720","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3390\/v4101878","article-title":"Forty-five years of Marburg virus research","volume":"4","author":"Brauburger","year":"2012","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0725","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41541-020-00226-y","article-title":"Modified vaccinia Ankara vaccine expressing Marburg virus-like particles protects guinea pigs from lethal Marburg virus infection","volume":"5","author":"Malherbe","year":"2020","journal-title":"npj Vaccines"},{"issue":"2","key":"10.1016\/j.jmb.2023.168173_b0730","doi-asserted-by":"crossref","first-page":"e1007564","DOI":"10.1371\/journal.ppat.1007564","article-title":"Complete protection of the BALB\/c and C57BL\/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine","volume":"15","author":"Rahim","year":"2019","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0735","first-page":"1","article-title":"Lassa fever in West African sub-region: an overview","volume":"44","author":"Ogbu","year":"2007","journal-title":"J. Vector Borne Dis."},{"issue":"36","key":"10.1016\/j.jmb.2023.168173_b0740","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1016\/j.vaccine.2019.07.023","article-title":"A vaccine based on recombinant modified Vaccinia Ankara containing the nucleoprotein from Lassa virus protects against disease progression in a guinea pig model","volume":"37","author":"Kennedy","year":"2019","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.jmb.2023.168173_b0745","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3390\/pathogens8030133","article-title":"A single dose of modified vaccinia Ankara expressing lassa virus-like particles protects mice from lethal intra-cerebral virus challenge","volume":"8","author":"Salvato","year":"2019","journal-title":"Pathogens."},{"key":"10.1016\/j.jmb.2023.168173_b0750","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.coviro.2014.01.010","article-title":"MERS: emergence of a novel human coronavirus","volume":"5","author":"Raj","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.jmb.2023.168173_b0755","unstructured":"WHO. Middle East respiratory syndrome coronavirus (MERS-CoV) 2023 Available from: https:\/\/www.who.int\/health-topics\/middle-east-respiratory-syndrome-coronavirus-mers#tab=tab_1."},{"issue":"8","key":"10.1016\/j.jmb.2023.168173_b0760","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S1473-3099(18)30127-0","article-title":"Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission","volume":"18","author":"Hui","year":"2018","journal-title":"Lancet Infect. Dis."},{"issue":"8","key":"10.1016\/j.jmb.2023.168173_b0765","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.3390\/vaccines10081330","article-title":"Immunogenicity of high-dose MVA-based MERS vaccine candidate in mice and camels","volume":"10","author":"Alharbi","year":"2022","journal-title":"Vaccines (Basel)."},{"issue":"7","key":"10.1016\/j.jmb.2023.168173_b0770","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1473-3099(20)30248-6","article-title":"Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial","volume":"20","author":"Koch","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"7","key":"10.1016\/j.jmb.2023.168173_b0775","article-title":"Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine","volume":"3","author":"Weskamm","year":"2022","journal-title":"Cell Rep Med."},{"issue":"20","key":"10.1016\/j.jmb.2023.168173_b0780","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa030747","article-title":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome","volume":"348","author":"Drosten","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jmb.2023.168173_b0785","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00253-007-1073-y","article-title":"Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus","volume":"76","author":"Ba","year":"2007","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"17","key":"10.1016\/j.jmb.2023.168173_b0790","doi-asserted-by":"crossref","first-page":"6641","DOI":"10.1073\/pnas.0401939101","article-title":"Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice","volume":"101","author":"Bisht","year":"2004","journal-title":"PNAS"},{"issue":"5","key":"10.1016\/j.jmb.2023.168173_b0795","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1128\/JVI.79.5.2678-2688.2005","article-title":"Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region","volume":"79","author":"Chen","year":"2005","journal-title":"J. Virol."},{"issue":"17\u201318","key":"10.1016\/j.jmb.2023.168173_b0800","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/j.vaccine.2005.01.033","article-title":"Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets","volume":"23","author":"Czub","year":"2005","journal-title":"Vaccine"},{"issue":"51","key":"10.1016\/j.jmb.2023.168173_b0805","doi-asserted-by":"crossref","first-page":"6678","DOI":"10.1016\/j.vaccine.2008.09.006","article-title":"A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus","volume":"26","author":"Schulze","year":"2008","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0810","doi-asserted-by":"crossref","first-page":"e2010","DOI":"10.1002\/rmv.2010","article-title":"Emerging trends of Nipah virus: A review","volume":"29","author":"Sharma","year":"2019","journal-title":"Rev. Med. Virol."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0815","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/v12010026","article-title":"A soluble version of nipah virus glycoprotein G delivered by vaccinia virus MVA activates specific CD8 and CD4 T cells in mice","volume":"12","author":"Kalodimou","year":"2019","journal-title":"Viruses"},{"issue":"42","key":"10.1016\/j.jmb.2023.168173_b0820","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1016\/j.vaccine.2015.08.020","article-title":"Rift Valley fever virus: A review of diagnosis and vaccination, and implications for emergence in Europe","volume":"33","author":"Mansfield","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jmb.2023.168173_b0825","unstructured":"WHO. Rift valley fever 2023 Available from: https:\/\/www.who.int\/health-topics\/rift-valley-fever#tab=tab_1."},{"key":"10.1016\/j.jmb.2023.168173_b0830","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.antiviral.2014.05.020","article-title":"Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs","volume":"108","author":"Busquets","year":"2014","journal-title":"Antiviral Res."},{"issue":"7","key":"10.1016\/j.jmb.2023.168173_b0835","doi-asserted-by":"crossref","first-page":"e2309","DOI":"10.1371\/journal.pntd.0002309","article-title":"A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection","volume":"7","author":"Lopez-Gil","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0840","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/vaccines8010082","article-title":"MVA vectored vaccines encoding rift valley fever virus glycoproteins protect mice against lethal challenge in the absence of neutralizing antibody responses","volume":"8","author":"Lopez-Gil","year":"2020","journal-title":"Vaccines (Basel)."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0845","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13567-018-0516-z","article-title":"Efficacy of different DNA and MVA prime-boost vaccination regimens against a Rift Valley fever virus (RVFV) challenge in sheep 12 weeks following vaccination","volume":"49","author":"Lorenzo","year":"2018","journal-title":"Vet. Res."},{"key":"10.1016\/j.jmb.2023.168173_b0850","unstructured":"WHO. Zika virus disease 2023 Available from: https:\/\/www.who.int\/health-topics\/zika-virus-disease#tab=tab_1."},{"key":"10.1016\/j.jmb.2023.168173_b0855","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijid.2016.05.014","article-title":"Zika virus, vectors, reservoirs, amplifying hosts, and their potential to spread worldwide: what we know and what we should investigate urgently","volume":"48","author":"Vorou","year":"2016","journal-title":"Int. J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0860","doi-asserted-by":"crossref","first-page":"17385","DOI":"10.1038\/s41598-018-35724-6","article-title":"A vaccine based on a modified vaccinia virus Ankara vector expressing zika virus structural proteins controls zika virus replication in mice","volume":"8","author":"Perez","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0865","doi-asserted-by":"crossref","first-page":"14769","DOI":"10.1038\/s41598-017-15039-8","article-title":"A Zika vaccine targeting NS1 protein Protects immunocompetent adult mice in a lethal challenge model","volume":"7","author":"Brault","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.jmb.2023.168173_b0870","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3390\/vaccines10040533","article-title":"Protective CD8+ T Cell response induced by modified vaccinia virus Ankara delivering ebola virus nucleoprotein","volume":"10","author":"Kupke","year":"2022","journal-title":"Vaccines (Basel)."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0875","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41598-017-19041-y","article-title":"A single dose of modified vaccinia Ankara expressing ebola virus like particles protects nonhuman primates from lethal ebola virus challenge","volume":"8","author":"Domi","year":"2018","journal-title":"Sci. Rep."},{"issue":"16","key":"10.1016\/j.jmb.2023.168173_b0880","doi-asserted-by":"crossref","first-page":"8651","DOI":"10.1128\/JVI.00614-15","article-title":"Protective efficacy of recombinant modified vaccinia virus Ankara delivering middle east respiratory syndrome coronavirus spike glycoprotein","volume":"89","author":"Volz","year":"2015","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.jmb.2023.168173_b0885","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3390\/pathogens8040216","article-title":"Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers","volume":"8","author":"Lopez-Camacho","year":"2019","journal-title":"Pathogens."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0890","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1080\/22221751.2021.1951624","article-title":"The combined vaccination protocol of DNA\/MVA expressing Zika virus structural proteins as efficient inducer of T and B cell immune responses","volume":"10","author":"Perez","year":"2021","journal-title":"Emerg. Microbes Infect."},{"issue":"3","key":"10.1016\/j.jmb.2023.168173_b0895","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3390\/ph15030354","article-title":"Low immune Cross-reactivity between west nile virus and a Zika virus vaccine based on modified vaccinia virus Ankara","volume":"15","author":"Jimenez de Oya","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"10.1016\/j.jmb.2023.168173_b0900","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/21645515.2017.1264755","article-title":"A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks","volume":"13","author":"Shukarev","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"issue":"8","key":"10.1016\/j.jmb.2023.168173_b0905","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/infdis\/jiy639","article-title":"Safety and immunogenicity of a heterologous prime-boost ebola virus vaccine regimen in healthy adults in the United Kingdom and senegal","volume":"219","author":"Venkatraman","year":"2019","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0910","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41541-021-00280-0","article-title":"Durable natural killer cell responses after heterologous two-dose Ebola vaccination","volume":"6","author":"Wagstaffe","year":"2021","journal-title":"npj Vaccines"},{"issue":"4","key":"10.1016\/j.jmb.2023.168173_b0915","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","article-title":"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial","volume":"21","author":"Pollard","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"10","key":"10.1016\/j.jmb.2023.168173_b0920","doi-asserted-by":"crossref","first-page":"e0274906","DOI":"10.1371\/journal.pone.0274906","article-title":"First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study","volume":"17","author":"Bockstal","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0925","doi-asserted-by":"crossref","first-page":"e1003865","DOI":"10.1371\/journal.pmed.1003865","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial","volume":"19","author":"Anywaine","year":"2022","journal-title":"PLoS Med."},{"issue":"4","key":"10.1016\/j.jmb.2023.168173_b0930","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/infdis\/jiaa586","article-title":"Safety and immunogenicity of heterologous and homologous 2-dose regimens of adenovirus serotype 26- and modified vaccinia Ankara-vectored ebola vaccines: A randomized, controlled phase 1 study","volume":"226","author":"Goldstein","year":"2022","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0935","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1473-3099(21)00128-6","article-title":"Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial","volume":"22","author":"Afolabi","year":"2022","journal-title":"Lancet Infect. Dis."},{"issue":"3","key":"10.1016\/j.jmb.2023.168173_b0940","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1473-3099(22)00594-1","article-title":"Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial","volume":"23","author":"Manno","year":"2023","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0945","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1473-3099(21)00125-0","article-title":"Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial","volume":"22","author":"Ishola","year":"2022","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b0950","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMp1916753","article-title":"Four decades of HIV\/AIDS - Much Accomplished, Much to Do","volume":"383","author":"Fauci","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jmb.2023.168173_b0955","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/21645515.2016.1276138","article-title":"Progress in HIV vaccine development","volume":"13","author":"Hsu","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jmb.2023.168173_b0960","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/503978","article-title":"HIV vaccine research: the challenge and the way forward","volume":"2015","author":"Wang","year":"2015","journal-title":"J. Immunol. Res."},{"issue":"2","key":"10.1016\/j.jmb.2023.168173_b0965","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/14760584.2020.1718497","article-title":"Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges","volume":"19","author":"Pitisuttithum","year":"2020","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.jmb.2023.168173_b0970","unstructured":"HVTN 702 Clinical Trial of an HIV Vaccine Stopped [press release]. Geneva, Switzerland,2020."},{"issue":"23","key":"10.1016\/j.jmb.2023.168173_b0975","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"310","key":"10.1016\/j.jmb.2023.168173_b0980","doi-asserted-by":"crossref","first-page":"310rv7","DOI":"10.1126\/scitranslmed.aac7732","article-title":"Immune correlates of vaccine protection against HIV-1 acquisition","volume":"7","author":"Corey","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"46","key":"10.1016\/j.jmb.2023.168173_b0985","doi-asserted-by":"crossref","first-page":"8417","DOI":"10.1016\/j.vaccine.2011.08.001","article-title":"Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania","volume":"29","author":"Bakari","year":"2011","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.jmb.2023.168173_b0990","doi-asserted-by":"crossref","first-page":"e0155702","DOI":"10.1371\/journal.pone.0155702","article-title":"Boosting with subtype C CN54rgp140 protein adjuvanted with glucopyranosyl lipid adjuvant after priming with HIV-DNA and HIV-MVA Is safe and enhances immune responses: A phase I trial","volume":"11","author":"Joachim","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jmb.2023.168173_b0995","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1089\/aid.2016.0251","article-title":"Three-year durability of immune responses induced by HIV-DNA and HIV-modified vaccinia virus Ankara and effect of a late HIV-modified vaccinia virus ankara boost in tanzanian volunteers","volume":"33","author":"Joachim","year":"2017","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"4","key":"10.1016\/j.jmb.2023.168173_b1000","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3390\/vaccines8040681","article-title":"Frequent and durable anti-HIV envelope VIV2 IgG responses induced by HIV-1 DNA priming and HIV-MVA boosting in healthy Tanzanian volunteers","volume":"8","author":"Joachim","year":"2020","journal-title":"Vaccines (Basel)."},{"issue":"6","key":"10.1016\/j.jmb.2023.168173_b1005","doi-asserted-by":"crossref","first-page":"e0131748","DOI":"10.1371\/journal.pone.0131748","article-title":"HIV-DNA given with or without intradermal electroporation is safe and highly immunogenic in healthy swedish HIV-1 DNA\/MVA vaccinees: A phase I randomized trial","volume":"10","author":"Nilsson","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jmb.2023.168173_b1010","doi-asserted-by":"crossref","first-page":"e0119629","DOI":"10.1371\/journal.pone.0119629","article-title":"Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial","volume":"10","author":"Munseri","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jmb.2023.168173_b1015","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/aid.2017.0121","article-title":"Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial","volume":"34","author":"Viegas","year":"2018","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"11","key":"10.1016\/j.jmb.2023.168173_b1020","doi-asserted-by":"crossref","first-page":"e0206838","DOI":"10.1371\/journal.pone.0206838","article-title":"Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140\/GLA vaccines in a phase II randomized factorial trial design","volume":"13","author":"Viegas","year":"2018","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.jmb.2023.168173_b1025","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/infdis\/jix456","article-title":"Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost","volume":"216","author":"Ake","year":"2017","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.jmb.2023.168173_b1030","doi-asserted-by":"crossref","first-page":"e55831","DOI":"10.1371\/journal.pone.0055831","article-title":"Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers","volume":"8","author":"Mehendale","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jmb.2023.168173_b1035","doi-asserted-by":"crossref","first-page":"e0213911","DOI":"10.1371\/journal.pone.0213911","article-title":"Induction and maintenance of bi-functional (IFN-gamma + IL-2+ and IL-2+ TNF-alpha+) T cell responses by DNA prime MVA boosted subtype C prophylactic vaccine tested in a Phase I trial in India","volume":"14","author":"Munusamy Ponnan","year":"2019","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jmb.2023.168173_b1040","doi-asserted-by":"crossref","first-page":"e0203037","DOI":"10.1371\/journal.pone.0203037","article-title":"Induction of circulating T follicular helper cells and regulatory T cells correlating with HIV-1 gp120 variable loop antibodies by a subtype C prophylactic vaccine tested in a Phase I trial in India","volume":"13","author":"Munusamy Ponnan","year":"2018","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.jmb.2023.168173_b1045","doi-asserted-by":"crossref","first-page":"e0179597","DOI":"10.1371\/journal.pone.0179597","article-title":"Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults","volume":"12","author":"Buchbinder","year":"2017","journal-title":"PLoS One"},{"issue":"46","key":"10.1016\/j.jmb.2023.168173_b1050","doi-asserted-by":"crossref","first-page":"8309","DOI":"10.1016\/j.vaccine.2011.08.098","article-title":"Safety and immunogenicity of a modified pox vector-based HIV\/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)","volume":"29","author":"Garcia","year":"2011","journal-title":"Vaccine"},{"issue":"21","key":"10.1016\/j.jmb.2023.168173_b1055","doi-asserted-by":"crossref","first-page":"11468","DOI":"10.1128\/JVI.05165-11","article-title":"The HIV\/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens","volume":"85","author":"Gomez","year":"2011","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.jmb.2023.168173_b1060","doi-asserted-by":"crossref","first-page":"e0186602","DOI":"10.1371\/journal.pone.0186602","article-title":"Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization","volume":"12","author":"Guardo","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jmb.2023.168173_b1065","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/mt.2013.248","article-title":"Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1","volume":"22","author":"Borthwick","year":"2014","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.jmb.2023.168173_b1070","doi-asserted-by":"crossref","first-page":"e0181382","DOI":"10.1371\/journal.pone.0181382","article-title":"Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA\/simian adenovirus\/MVA vaccine regimens","volume":"12","author":"Moyo","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jmb.2023.168173_b1075","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1128\/CVI.00717-15","article-title":"Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap","volume":"23","author":"Gray","year":"2016","journal-title":"Clin. Vaccine Immunol."},{"issue":"9","key":"10.1016\/j.jmb.2023.168173_b1080","doi-asserted-by":"crossref","first-page":"e0161753","DOI":"10.1371\/journal.pone.0161753","article-title":"Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants","volume":"11","author":"Churchyard","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jmb.2023.168173_b1085","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fimmu.2017.00149","article-title":"A comparative phase I study of combination, homologous subtype-C DNA, MVA, and Env gp140 protein\/adjuvant HIV vaccines in two immunization regimes","volume":"8","author":"Joseph","year":"2017","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.jmb.2023.168173_b1090","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/infdis\/jiy212","article-title":"First-in-human randomized, controlled trial of mosaic HIV-1 immunogens Delivered via a modified vaccinia Ankara vector","volume":"218","author":"Baden","year":"2018","journal-title":"J Infect Dis"},{"issue":"10143","key":"10.1016\/j.jmb.2023.168173_b1095","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13\u201319)","volume":"392","author":"Barouch","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jmb.2023.168173_b1100","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.4049\/jimmunol.2101076","article-title":"T cell immunogenicity, gene expression profile, and safety of four heterologous prime-boost combinations of HIV vaccine candidates in healthy volunteers: results of the randomized multi-arm phase I\/II ANRS VRI01 trial","volume":"208","author":"Richert","year":"2022","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.jmb.2023.168173_b1105","doi-asserted-by":"crossref","first-page":"e0141456","DOI":"10.1371\/journal.pone.0141456","article-title":"A phase I randomized therapeutic MVA-B vaccination improves the magnitude and quality of the T cell immune responses in HIV-1-infected subjects on HAART","volume":"10","author":"Gomez","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jmb.2023.168173_b1110","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/jac\/dkv046","article-title":"Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1","volume":"70","author":"Mothe","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"issue":"9","key":"10.1016\/j.jmb.2023.168173_b1115","doi-asserted-by":"crossref","first-page":"e0184929","DOI":"10.1371\/journal.pone.0184929","article-title":"Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B","volume":"12","author":"Rosas-Umbert","year":"2017","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.jmb.2023.168173_b1120","doi-asserted-by":"crossref","first-page":"e0163164","DOI":"10.1371\/journal.pone.0163164","article-title":"DNA\/MVA Vaccination of HIV-1 Infected participants with viral suppression on antiretroviral therapy, followed by treatment interruption: elicitation of immune responses without control of re-emergent virus","volume":"11","author":"Thompson","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b1125","doi-asserted-by":"crossref","first-page":"21171","DOI":"10.7448\/IAS.20.1.21171","article-title":"Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects","volume":"20","author":"Hancock","year":"2017","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.jmb.2023.168173_b1130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eclinm.2019.05.009","article-title":"Therapeutic Vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)","volume":"11","author":"Mothe","year":"2019","journal-title":"EClinicalMedicine."},{"key":"10.1016\/j.jmb.2023.168173_b1135","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3389\/fimmu.2020.00823","article-title":"HIVconsv vaccines and romidepsin in early-treated HIV-1-infected individuals: safety, immunogenicity and effect on the viral reservoir (Study BCN02)","volume":"11","author":"Mothe","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jmb.2023.168173_b1140","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3389\/fimmu.2020.00418","article-title":"In vivo effects of romidepsin on T-cell activation, apoptosis and function in the BCN02 HIV-1 Kick&Kill clinical trial","volume":"11","author":"Rosas-Umbert","year":"2020","journal-title":"Front. Immunol."},{"issue":"10227","key":"10.1016\/j.jmb.2023.168173_b1145","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S0140-6736(19)32990-3","article-title":"Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial","volume":"395","author":"Fidler","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jmb.2023.168173_b1150","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41591-020-0774-y","article-title":"Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption","volume":"26","author":"Colby","year":"2020","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.jmb.2023.168173_b1155","doi-asserted-by":"crossref","first-page":"e1008522","DOI":"10.1371\/journal.ppat.1008522","article-title":"Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03\/ANRS VAC20 Phase I\/II Trial","volume":"16","author":"Levy","year":"2020","journal-title":"PLoS Pathog."},{"issue":"6","key":"10.1016\/j.jmb.2023.168173_b1160","doi-asserted-by":"crossref","first-page":"e0128626","DOI":"10.1371\/journal.pone.0128626","article-title":"Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity","volume":"10","author":"Alharbi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jmb.2023.168173_b1165","doi-asserted-by":"crossref","first-page":"e11406","DOI":"10.1371\/journal.pone.0011406","article-title":"Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens","volume":"5","author":"N\u00e1jera","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jmb.2023.168173_b1170","doi-asserted-by":"crossref","first-page":"e25674","DOI":"10.1371\/journal.pone.0025674","article-title":"Improved NYVAC-based vaccine vectors","volume":"6","author":"Kibler","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jmb.2023.168173_b1175","doi-asserted-by":"crossref","first-page":"e16819","DOI":"10.1371\/journal.pone.0016819","article-title":"Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors","volume":"6","author":"Quakkelaar","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jmb.2023.168173_b1180","doi-asserted-by":"crossref","first-page":"e02182","DOI":"10.1128\/JVI.02182-16","article-title":"HIV\/AIDS vaccine candidates based on replication-competent recombinant poxvirus NYVAC-C-KC expressing trimeric gp140 and Gag-derived virus-like particles or lacking the viral molecule B19 that inhibits type I interferon activate relevant HIV-1-Specific B","volume":"91","author":"Garc\u00eda-Arriaza","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2023.168173_b1185","first-page":"e01513","article-title":"Replication-competent NYVAC-KC Yields improved immunogenicity to HIV-1 antigens in rhesus macaques compared to nonreplicating NYVAC","volume":"93","author":"Kibler","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2023.168173_b1190","doi-asserted-by":"crossref","first-page":"e01648","DOI":"10.1128\/JVI.01648-18","article-title":"Novel modified vaccinia virus Ankara vector expressing anti-apoptotic gene B13R delays apoptosis and enhances humoral responses","volume":"93","author":"Chea","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2023.168173_b1195","doi-asserted-by":"crossref","first-page":"8743","DOI":"10.1128\/JVI.00604-10","article-title":"Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses","volume":"84","author":"Baur","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2023.168173_b1200","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.vaccine.2007.11.036","article-title":"Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines","volume":"26","author":"Wyatt","year":"2008","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b1205","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/21645515.2018.1513439","article-title":"Poxviral promoters for improving the immunogenicity of MVA delivered vaccines","volume":"15","author":"Alharbi","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jmb.2023.168173_b1210","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.2144\/97236st07","article-title":"Compact, synthetic, vaccinia virus early\/late promoter for protein expression","volume":"23","author":"Chakrabarti","year":"1997","journal-title":"Biotechniques"},{"key":"10.1016\/j.jmb.2023.168173_b1215","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1099\/vir.0.057299-0","article-title":"New vaccinia virus promoter as a potential candidate for future vaccines","volume":"94","author":"Di Pilato","year":"2013","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.jmb.2023.168173_b1220","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3390\/vaccines10081172","article-title":"Intranasal immunization with a vaccinia virus vaccine vector expressing pre-fusion stabilized SARS-CoV-2 spike fully protected mice against lethal challenge with the heavily mutated mouse-adapted SARS2-N501YMA30 strain of SARS-CoV-2","volume":"10","author":"Kibler","year":"2022","journal-title":"Vaccines."},{"issue":"22","key":"10.1016\/j.jmb.2023.168173_b1225","doi-asserted-by":"crossref","first-page":"12672","DOI":"10.1128\/JVI.78.22.12672-12676.2004","article-title":"Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets","volume":"78","author":"Weingartl","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2023.168173_b1230","doi-asserted-by":"crossref","first-page":"e0192312","DOI":"10.1371\/journal.pone.0192312","article-title":"A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates","volume":"13","author":"Callendret","year":"2018","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.jmb.2023.168173_b1235","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/JVI.77.11.6305-6313.2003","article-title":"Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene","volume":"77","author":"Casimiro","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2023.168173_b1240","doi-asserted-by":"crossref","first-page":"8525","DOI":"10.1128\/JVI.01265-15","article-title":"Head-to-head comparison of poxvirus NYVAC and ALVAC vectors expressing identical HIV-1 clade C immunogens in prime-boost combination with env protein in nonhuman primates","volume":"89","author":"Garc\u00eda-Arriaza","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2023.168173_b1245","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1016\/j.vaccine.2006.09.090","article-title":"Head-to-head comparison on the immunogenicity of two HIV\/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1IIIB Gag-Pol-Nef proteins of clade B","volume":"25","author":"G\u00f3mez","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jmb.2023.168173_b1250","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3390\/vaccines7040208","article-title":"An MVA vector expressing HIV-1 envelope under the control of a potent vaccinia virus promoter as a promising strategy in HIV\/AIDS vaccine design","volume":"7","author":"P\u00e9rez","year":"2019","journal-title":"Vaccines."},{"key":"10.1016\/j.jmb.2023.168173_b1255","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3390\/vaccines8010070","article-title":"Deletion of vaccinia virus A40R gene improves the immunogenicity of the HIV-1 vaccine candidate MVA-B","volume":"8","author":"P\u00e9rez","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.jmb.2023.168173_b1260","doi-asserted-by":"crossref","first-page":"e12395","DOI":"10.1371\/journal.pone.0012395","article-title":"Immunogenic profiling in mice of a HIV\/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions","volume":"5","author":"Garc\u00eda-Arriaza","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jmb.2023.168173_b1265","doi-asserted-by":"crossref","first-page":"e74831","DOI":"10.1371\/journal.pone.0074831","article-title":"Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in Mice of the HIV\/AIDS vaccine candidate NYVAC-C","volume":"8","author":"Perdiguero","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jmb.2023.168173_b1270","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/v10010007","article-title":"Immune modulation of NYVAC-based HIV vaccines by combined deletion of viral genes that act on several signalling pathways","volume":"10","author":"G\u00f3mez","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.jmb.2023.168173_b1275","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1128\/JVI.00246-12","article-title":"Deletion of specific Immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques","volume":"86","author":"Garber","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2023.168173_b1280","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1128\/JVI.03061-14","article-title":"Interleukin-1- and Type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins","volume":"89","author":"Delaloye","year":"2015","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.jmb.2023.168173_b1285","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1128\/JVI.06684-11","article-title":"Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV\/AIDS vaccine candidate NYVAC-C in mice","volume":"86","author":"Gomez","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2023.168173_b1290","doi-asserted-by":"crossref","first-page":"e24244","DOI":"10.1371\/journal.pone.0024244","article-title":"A candidate HIV\/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses","volume":"6","author":"Garc\u00eda-Arriaza","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jmb.2023.168173_b1295","doi-asserted-by":"crossref","first-page":"e32220","DOI":"10.1371\/journal.pone.0032220","article-title":"Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein","volume":"7","author":"Falivene","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jmb.2023.168173_b1300","doi-asserted-by":"crossref","first-page":"e48524","DOI":"10.1371\/journal.pone.0048524","article-title":"Deletion of the viral anti-apoptotic gene F1L in the HIV\/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens","volume":"7","author":"Perdiguero","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jmb.2023.168173_b1305","doi-asserted-by":"crossref","first-page":"e66894","DOI":"10.1371\/journal.pone.0066894","article-title":"Improving adaptive and memory immune responses of an HIV\/AIDS vaccine candidate MVA-B by deletion of vaccinia virus genes (C6L and K7R) blocking interferon signaling pathways","volume":"8","author":"Garc\u00eda-Arriaza","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jmb.2023.168173_b1310","doi-asserted-by":"crossref","first-page":"e00575","DOI":"10.1128\/JVI.00575-17","article-title":"Distinct roles of vaccinia virus NF-\u03baB inhibitor proteins A52, B15, and K7 in the immune response","volume":"91","author":"Di Pilato","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2023.168173_b1315","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1128\/JVI.02723-13","article-title":"Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens","volume":"88","author":"Garcia-Arriaza","year":"2014","journal-title":"J. Virol."}],"container-title":["Journal of Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022283623002607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022283623002607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T06:27:49Z","timestamp":1762669669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022283623002607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":263,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0022283623002607"],"URL":"https:\/\/doi.org\/10.1016\/j.jmb.2023.168173","relation":{},"ISSN":["0022-2836"],"issn-type":[{"value":"0022-2836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmb.2023.168173","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"168173"}}